EvaluatePharma - Novartis - Worldwide

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile



Profile	Novartis (NYSE: NVS), created through the December 1996 merger of Swiss companies Sandoz & Ciba-Geigy. Business segments include: Pharmaceuticals, Vaccines & Diagnostics, Sandoz (Generics) & Consumer Health (includes CIBA Vision and Animal Health).
Listed or Private Company	Listed
Company Classification	Global Majors; Generic; Med Tech
Company Website	Website

Full Company Profile Information

EventAnalyzer - Last Key Event


Closing Price DateClosing Price Date	EventAnalyzer Note	Market Cap (US $m)	Change (%)	Change (+$m)
8/10/2010	9 Aug: Company receives approval from EU regulators to buy a stake in Alcon, making it easier for the company to take full control later; Novartis to acquire 52% from Nestle to add to its 25% stake.	113,713	1.5%	1,665

Top 3 Products (Worldwide Sales 2007/08)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2007	2008	2008
1	Diovan	valsartan	Angiotensin II antagonists	5,012²	5,740³	+15%
2	Gleevec/Glivec	imatinib mesylate	Other cytostatics	3,050⁴	3,670⁵	+20%
3	Zometa	zoledronic acid	Bone calcium regulators	1,297⁶	1,382⁷	+7%

Note: Shaded Cells⁸

RX Sales Chart

Novartis	Data		Growth
	2007	2008	2008
Revenues By Segment
Pharmaceuticals
Pharmaceuticals Sales (In-depth)
Rx & OTC Pharmaceuticals
Prescription (Rx) Pharmaceuticals⁹	31,573¹⁰	34,462¹¹	+9%

Therapy Area Focus in 2008

Novartis
	2008
WW Rx & OTC Sales By Therapy Area
Main Categories
Cardiovascular¹²	8,183¹³
Central Nervous System¹⁴	3,262¹⁵
Dermatology	152
Endocrine	1,513
Gastro-Intestinal	198
Genito-Urinary	399
Musculoskeletal	2,631
Oncology & Immunomodulators	6,461
Respiratory	793
Sensory Organs¹⁶	1,288¹⁷
Systemic Anti-Infectives	2,078
Various	589
Other Rx & OTC Pharma	9,928

EvaluatePharma® Coverage of Marketed and Pipeline Products


	Product Count
Novartis ¹⁸	743

2009 Product Sales analysis
2009 Pharmaceutical Sales
2009 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases


EP Vantage - last 6 months

Idenix on hold after FDA slams brakes on lead hep C candidates (September 09, 2010)

ESC - Elinogrel shows its stuff but Brilinta still the star (August 31, 2010)

Preview - ESC to throw up more than just the hot topics (August 26, 2010)

Gene therapy players sensing light at the end of the tunnel (August 25, 2010)

Vectura finds bearing in post-Advair era with GSK deal (August 06, 2010)

Displaying 5 out of a possible 44 unique stories.
Results Sorted By date
Display All Stories

Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXX (XXX X.X XXXXXXX, +XX% XX) XXXXXXX XXXXXXX XXXXXXXXX XXXXXXXXX XX XXXX XX XXX XXXXX XXXXXXX XXX X XXXXXXX XXX XXX XXXXX XXXX. XXXXXX XXX XXXXXXXXXXXX XXXXX XXXXXX XX XXX XXXXXXXXXXX XXX XXXXXXXX XXXX XXXXXXXXXXXX XXX XXXXXX XX XXX XXXXX’X XX. X XXXXXXX XXXX XXXXX XXXXXXXX XXXXXXXX. XXXX XXX XXXXXXXXX, XXXXXXXXXXXX XXX XX, XXXXX XXX XXXXXXX, XXXXXXXXX XXXXXX-XXXXX XXXXXX. XXXXXX XXXX X XX% XXXXX XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXX (XXXX), XXX XXXXXXX-XXXXXXX XXXXXXX XX XXX XX XXXXXXXXXXXXXXXX XXXXXX. XX-XXXXXX/XXXXXX XXX, X XXXXXX-XXXXXX XXXXXXXXXXX XXXX X XXXXXXXX, XXX XXXXXX XX XXXXXXX XXX XX XXXXXXXX XXXXXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXXX XXX-XXX:
XXXXXX ($X.X XXXXXXX, +XX% XX), XXX XXXXX’X XXX-XXXXXXX XXXXXXX XXXXXXXX XXX XXXX XXXXX XXXXXXXX, XXXX XXXXXXXX XX XXX XXX XXXXXXX XXXXXXXXX, XXXX XXXXX XXXXXXX XXX XX XXX XXXXXXXXXX XXX XXXXX XX% XX XXX XXXXX XXX XXXXXXXXXX XX% XX XXXXXX. XX XXXXX XXXX XXXX XX% XX XXXXXX XXXXXXXXXXXX XXX XX% XXXXXXX XXXXX XX XXX XXXXXXXXXXX XXXXXXXX XXXXXXXX (XXXX) XXXXXXX XXXXXXX XX XXXXXXX XXXXXXXX XX XXX XXXXXXXXXXXXXXXX XXXXXX, XXXXXXXXX XXXX. XXXXXX XXX XXXXXXXXX XXXX XXX XXXXXX XX XXX XXXX XXXXXXXX XX XXX XXX XXXXX XXXXXXXX XX XXXXX XXXX XXXXX XXXXXXXX, XXXX-XXXX XXXXX XXXXXX XXXXXXXXX XXX XXXXX XXXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXXX/XXXXXX (XXX X.X XXXXXXX, +XX% XX), X XXXXXXX XXX XXXXXXX XXXXX XX XXXXXXX XXXXXXX XXXXXXXX (XXX) XXX XXXXXXXXXXXXXXXX XXXXXXX XXXXXX (XXXX), XXXXXXXXXX XXX XXXXXXXXXX XX XXXXXXX XXXXXXXX XXXX XXXXX XXX XXXXX XXXXX-XXXXX XXXXX XX XXXXXX. XXX XXXX XXXX XXX XXXX XXXXX XX XXXXXXXX XXXX XXXXX XXXXXXXXX XXXXXXXXXXXX XXXXXXXXXX-XXXXXXXX XXX (XX+ XXX) XXXXXX XXXXXXX/XXXXXX XXXXXX XXXXXXX XXXXXXXXXXX XX XXXX XXXXXXXX XXXXXX XXXXXXXXXX XX XXX XXXXX XXXX XX XXXXXXXXX XXX XXXX XX% XX XXXXXXX/XXXXXX XXXXXXXX XX XXX XXXXX XXXX XXXXX XXXXX. XXXXXXX/XXXXXX XXX XXXX XXXXXXXXX XXXX XXXXX XXX XX XXXXXXXX XXXX XXXX XXX XX XXXXXXX XXXX XXXXXXXX. XXXXXXXXXXX XX XXX XXX XXXXXX XX XXXX XXX XXXXXX XXXXXX XX XXXXXXXXXX XXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XXX:
XXXXXXX/XXXXXX ($X.X XXXXXXX, +XX% XX), X XXXXXXXX XXXXXXX XXX XXXXXXX XXXXX XX XXXXXXX XXXXXXX XXXXXXXX (XXX) XXX XXXXXXXXXXXXXXXX XXXXXXX XXXXXX (XXXX), XXXXXXXXX XXXXX XXXXXX-XXXXX XXXXXX XX XXXX XXXXX XX XXXXXX XXXXXXXX XXXX XXX XXX XXXXXX XX XXX XXXXXXX XXXXXXX XXX XXXXX XXX XXXXX XXXX-XXXXXXXXXXX XXXXX XX XXXXXX. XX XXXXXXXX XXXX, XXXXXXX XXXXXX XXX XXXXX XXX-XXXXXXXX XXXXXXXXX XXX XXX XXXXX XXXX XXXXXXX (XXXXXXXX XXXXXXX). XXXXXXX XXXXXXXXXXX XXXX XXXX XX XXX XX, XXXXXXXXXXX XXX XXXXX XXXXXXXXX, XXXX XXXXXXXXXX XXXXXXXX XXX XXXX XXXXXXXXXX XXXXXXXX XX XXXX. XXXX XXXX XXX XXXXXXXX XXXX XXXXX XX XXX XXXXXXXX XXXXXXX XX XXXXXXXXXX XXXXXXX XXXXXX XXXXXX XX% XX XXX XXXXXXXX XX XXX XXXXX XXXX XXXXX XXXXX XXXXX XXXXX XXXXX XXXXXXXXX XXXX XXXXXXX XXXX XXXXXXX, XXXXXXXXXXXXX XXX XXXXXXX XXXXXXX XXXXXXXX XXXXXXXX XX XXXX XX XXXX XXXXXXX XXXX.

Company Specific NameCardiovascular

XXXXXXXX XX $X:
X) +XXXX XXXXX XXXXXXXXXXXXXX XXXXXXXX.

XXXXXX: XX XXXX XXXXXX XXXXXX:

XXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXX (XXX X.X XXXXXXX, –X% XX), XX XXXXXXXXXXX XXXXXXXXXXXXXX XXXXXXX XXX XXXXXXXX XXXX XXXXXX XXXX XXX XXXXXX XX XXX XXXXX, XXXXXXXXX X XXXXXX XXXXXXXXXXX XXXX XXXXX XXXX XXXXXX XXXXXXXXXX XXXXXX XXXX XX XXX XX XXX XXXXXX. XXXXXXX XXXXXX XXX XXXX XXXXX XX XXXXXXXXX XXX XXXXXX XXXX XXXX XXXXXXXX XXXXXXXXX XXXXXXXXX XXXX XXXXXXXXXX XXX XXX X XXXXXXX XXXXXX XX XXXXXXX. XXXXXXX, XXXX XXXXX XXX XXXXXXXX XX XXXXXXXXXX XXX XX XXXXXXXX XXXX XXXX XXXXXX XX XXXX XX XXXXX XXXXXX XX XXXXX XXX XXXXXXX XXXXXXX XXX XX XXX XXXXXX. XX XXXXXXXX, XXX XX XXXX XXX XXXX XXXXXXXXXXXXXX XXXXXXX XXXXXX XX XXXXXXXXXX XXX XXXXXX XX XXXXXXXXX XXXXXXXXXXX XXXXX XXXX XXXXXXXXX XXX XXXXXXXXXX XX XXXXXXXXX XXXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XXX:
XXXXXX (XXX X.X XXXXXXX, +X% XX), XX XXXXXXXXXXX XXXXXXXXXXXXXX XXXXXXX XXX XXXXXXXX XXXX XXXXXX XXXX XXX XXXXXX XX XXX XXXXX, XXXXXXXX XX XXXXXX XXXXXX XX XXXXXXXX XXXXXXXXXX XXX XXXXXXXX XXXXXXXXXXX XXX XXX XXXX XXXXXXX XXXXXXXXXXX XXXXXXXXXX XXXXXXXX XX XXXX XXXXXXX. X XXXXX XX XXXXXXXXXXXXX XXXXX XXXX XXXXXXX-XXXXXXXXX, XXXXX-XXXXX XXXXXX XXXXXX XXXXXX XXX XXXXXXXX XX XXXXXX XX XXXXXXX XXXXXXX XXXXX XXXXXXX XXXXXXXXXXXXX XXXXXXX XXX XXXX XX XXXXXXXXXX XX XXXXX XXXXXX XXXXXXXX XXXXXXXX XXXX XXXXXXX XXXXXXX XXXXX. XXXXX XXX XXXX XX XXXX XXXXXX XXX XXXXXXXX XX XXXXXX XX XXXXXXXX XXXXXXXXXXXX XXXXXX XXXXXX XXXXXX XXXXXXX XXXXXXX XXX XXXX XX XXXXXX XXXXXX XXXX XXXXXXXXXXX XXXX XXXXXXXXXXXX XXXXX XX XXXXX XXXX XXXXX-XXXXX XXXXXXX. XXXX XXXXXXX XXX XXXXXXXX XX XXXXXX XXXXXXXXX XXXXXXXXXX XXXXXXXX XX XXXXXX.

Company Specific NameNeuroscience

XXXXXXXXXXXXXX® XXXXXXX:
XXXXXXXXXXXX XXXXX XX XXXXXX XXXXXXXXX XXXXXXXXXX XX XXXX XXXXXX XXXXXX.

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.

Company Specific NamePharmaceuticals; Generics (Retail), Vaccines

XXXXXXXX XX $X:
X) +XXXXX XXXXXXXXXXXXXXX.
X) +XXXX XXXXXX (XXXXXX XXXXXXXX; XXXXXXXXX XXXXXXX XXXXXXXXXX XXXXXXXX XXXXXXXX).
X) +XXXX.XX XXXXXXXX.
X) +XX.X XXXXX XX XXXXXXXX XXXXXXXXXXXXXXX' XXXXX.

XXXXXXXX XX $X:
X) +XXXXX XXXXXXXXXXXXXXX.
X) +XXXX XXXXXX (XXXXXX XXXXXXXX; XXXXXXXXX XXXXXXX XXXXXXXXXX XXXXXXXX XXXXXXXX).
X) +XXXX.XX XXXXXXXX.
X) +XX.XXX XXXXX XX XXXXXXXX XXXXXXXXXXXXXXX' XXXXX.

Company Specific NameOphthalmics

XXXXXXXXXXXXXX® XXXXXXX:
XXXXXXXXXX XX XXXXXXX XXXXX XXX XXXXXXXXXXXX XX XXXXXXXXX XX XXXX.